PepGen Inc. Class Action Lawsuit - PEPG

The filed complaint alleges that PepGen Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

In order to be eligible to join the PEPG class action lawsuit, you must have incurred a loss on shares of PepGen Inc. purchased during the class period listed above.

If you suffered a loss in PepGen Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until August 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.